Answers are grounded in this paper and cite their sources.
Randomized trial shows IP2018 improves erectile function and reduces depression in male rats, suggesting a dual benefit.
Introduction Erectile dysfunction (ED) is frequent in patients with major depressive disorder, low mood, and anxiety, or emerges as an adverse effect of antidepressant treatment. Therefore, there is an unmet need for treatment with an impact on both depression and sexual dysfunction. IP2018 inhibits serotonin and dopamine reuptake, and has an attractive safety profile based on early clinical trials. Objective The present study investigated whether IP2018 improves depression and erectile function in the same dose range. Methods IP2018 was investigated in two different mouse models for depression, the mouse forced swim test (mFST) and the mouse tail suspension test (mTST). Spontaneous increases in intracavernosal pressure (ICP) and mean arterial pressure (MAP) were measured, and the facilitator effect was determined by the ratio ICP/MAP as a measure of erectile function in male Wistar (younger, 6 weeks and adult, 11-13 weeks), and Sprague Dawley control and rats with spontaneous depression (Flinders Sensitive Line (FSL), besides reactivity studies in erectile tissue of Wistar adult rats. Results IP2018 treatment had a dose-dependent effect in the mFST and mTST models, suggesting an antidepressant effect. Stimulation of the cavernous nerve and measures of erectile response, including intracavernosal pressure over mean arterial pressure (ICP/MAP), revealed that erectile responses in FSL rats were significantly decreased compared to those in SD rats. In contrast to the selective serotonin reuptake inhibitor, fluoxetine, intravenous infusion of IP2018 (0.001-1 mg/kg) dose-dependently increased the number and the duration of spontaneous erections in Wistar rats. In comparison, only the 0.1 mg/kg dose increases the spontaneous erections in FSL rats to the same level as in controls. In isolated corpus cavernosum strips, IP2018 (1-30 μM) caused small relaxations that were inhibited by a nitric oxide synthase inhibitor, L-nitro-arginine, and potentiated by a PDE5 inhibitor, sildenafil. Conclusions IP2018 had an effect in mouse models for depression, and in contrast to an SSRI, it had a potent impact on erectile function in Wistar rats. Moreover, IP2018 (0.1 mg/kg) induced erections in a rat model with spontaneous depression and erectile dysfunction, as in control rats. These preclinical findings suggest that IP2018 in the same dose range has positive effects on both depression and erectile function and support that IP2018 should be tested further in patients with depression, low mood, or anxiety and concomitant sexual dysfunction. Disclosure Yes, this is sponsored by industry/sponsor: Initiator Pharma A/S Clarification: Industry funding only - investigator initiated and executed study Any of the authors act as a consultant, employee or shareholder of an industry for: Initiator Pharma
No takes yet. Share an insight, caveat, or question.
Steffensen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: